Papers by Peter Alexander Ljubenkov · AgingResearch.News

medRxiv6 Oct
When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantification and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy
Preprint: trial in peopleBiomarkers
Paper
medRxiv2 Oct
Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
Preprint: cohort study of 567 peopleBiomarkers
Paper
Frontiers in Neurology26 Aug
Considerations for using amyloid-targeting therapies for the treatment of early symptomatic Alzheimer's disease
ReviewInterventions
Paper
Annals of Clinical and Translational Neurology7 Aug
Arterial Spin-Labeling MRI at the Cortical-CSF Interface: A Novel Biomarker in Alzheimer Disease
Study in peopleBiomarkers
Paper

AAIC 2025 Abstract11 Jan
Large‐scale cerebrospinal fluid proteomics identifies molecular signatures of disease progression across Alzheimer's disease and sporadic frontotemporal lobar degeneration
Study in peopleBiomarkers
Paper
AAIC 2025 Abstract26 Dec
Clinical associations of CSF TMEM106B in familial and sporadic frontotemporal lobar degeneration
Study in peopleBiomarkers
Paper
AAIC 2025 Abstract24 Dec
Targeted proteomics via NULISAseq identifies blood‐detectable markers of disease progression in familial frontotemporal lobar degeneration
Study in peopleBiomarkers
Paper
AAIC 2025 Abstract23 Dec
Phase 1b/2a, 6‐month, randomized, double‐blind, placebo‐controlled study of the safety/tolerability and preliminary evidence of efficacy of a tau‐targeted therapeutic in patients with corticobasal syndrome
Interventions
Paper